QA: Mylan II B V in us_pharma/2019

Table of Contents

See also this year's filing and all EDGAR filings for this company.

PDF Report 0001623613_2020_Mylan_II_B_V.pdf

Logs

warning The EntityCommonStockSharesOutstanding does not exist industry.us_generic {}
warning Missing logo subcommand.report {}
info NetIncome node detected by revenue/expenses heuristic input.sec.calculation_linkbase.edgar_model_mapping {'net_inc_node': 'OperatingIncomeLoss'}

Graph

Absolute values for 0001623613, Mylan II B V

  xvar xval
0 AssetsCurrent 6,757,300,000
1 IntangibleAssetsNetIncludingGoodwill 21,240,500,000
2 PropertyPlantAndEquipmentNet 2,149,600,000
3 remainder_Assets 1,108,100,000
4 LiabilitiesCurrent 5,569,100,000
5 LiabilitiesNoncurrent 12,175,100,000
6 remainder_Liabilities 1,627,500,000
7 CostOfGoodsAndServicesSold 7,602,900,000
8 SellingGeneralAndAdministrativeExpense 2,563,600,000
9 ResearchAndDevelopmentExpense 639,900,000
10 remainder_Expenses -21,400,000
11 remainder_Revenues 11,500,500,000
12 remainder_NetIncome 0
13 remainder_ComprehensiveNetIncome -1,051,000,000
  yvar yval
0 Assets 31,255,500,000
1 Liabilities 19,371,700,000
2 Expenses 10,785,000,000
3 Revenues 11,500,500,000
4 StockholdersEquity 11,883,800,000
5 NetIncome 715,500,000
6 ComprehensiveNetIncome 190,000,000
7 BaseVar 36,981,850,000
8 EconomicCapitalRatiobeforeLimitedLiability 1.03
9 EconomicCapitalRatio 2.33

Edgar->Model Mapping

Feature Distribution

Change over Time